|
 |
European Pharmaceutical Contractor
|
| We estimate that the total market for CROs grew by over 11 per cent in the year 2003. This is quite similar to the growth that we reported for the year 2002 over 2001. Again, this is solid growth that, while not in the 20 per cent range witnessed in the mid-90s, is still the sign of a very healthy industry. The CRO market breaks down into .05 billion for clinical research related activities (58 per cent) and .38 billion (42 per cent) for preclinical toxicology and analytics; making a grand total of .43 billion that exceeds the magic billion mark for the first time. This sum is approximately equal to the UKOs import of fuel and lubricant bill, the total foreign trade of Pakistan or the amount New Zealand spends on drugs. In 2003, we saw that clinical research expanded less than preclinical - 8.8 per cent growth compared with 15.5 per cent. We believe that this is driven by an increase in the number of early stage compounds coming through from smaller companies. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Vindon Scientific on the Move
More info >> |
|
 |
